Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl-
- CAS No.
- 1254032-16-0
- Chemical Name:
- Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl-
- Synonyms
- AR-13503;Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl-
- CBNumber:
- CB18203950
- Molecular Formula:
- C19H19N3O2
- Molecular Weight:
- 321.37
- MDL Number:
- MOL File:
- 1254032-16-0.mol
| Boiling point | 649.2±55.0 °C(Predicted) |
|---|---|
| Density | 1.310±0.06 g/cm3(Predicted) |
| pka | 12.89±0.43(Predicted) |
| form | Solid |
| color | White to off-white |
| FDA UNII | 4MVW7F3BCT |
Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl- Chemical Properties,Uses,Production
Uses
(rac)-AR-13503 ((rac)-AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C). AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice[1][2].
in vivo
AR-13503 (1.25 mg/kg; i.p.; once daily for 5 days) in collaboration with Aflibercept (HY-108801), significantly decreases the development of aberrant neovascularization (NV)[1].
| Animal Model: | Oxygen-induced retinopathy (OIR) mice model (C57BL/6; 7-days-old)[1] |
| Dosage: | 1.25 mg/kg |
| Administration: | Intraperitoneal injection; once daily for 5 days |
| Result: | The combination group had a greater (~75%) reduction in NV than Aflibercept alone (~55%). |
References
[1] Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59(9): 205-205.
[2] Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59(9): 200-200.
Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl- Preparation Products And Raw materials
Raw materials
Preparation Products
Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +17819995354 | marketing@targetmol.com | United States | 19962 | 58 |
| ComMedX (Computational Medicine Beijing Co., Ltd.) | +86-18519000250 +86-18519000250 | zhanghu@commedx.com | China | 258 | 58 |
| Hubei Xinyang Medical Technology Co., Ltd | 15347293736 | 2853117764@qq.com | China | 10001 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29641 | 58 |
| commedx | 010-46598925 18519000250 | zhanghu@commedx.com | China | 269 | 58 |
| Jiangsu Aikon Biopharmaceutical R&D Co.,Ltd | 025-58851090 17714375163 | 2881759498@qq.com | China | 13011 | 58 |
| Hubei Rhema Reference Materials Technology Co., Ltd. | 15787875101 | 645977340@qq.com | China | 9478 | 58 |
